Key terms
About SPRB
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SPRB news
Mar 20
2:02am ET
Spruce Biosciences’ Compliance Hurdle: Navigating Sarbanes-Oxley to Protect Market Value
Mar 18
12:30am ET
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Mar 14
6:30am ET
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Mar 14
12:35am ET
Buy Rating Affirmed for Spruce Biosciences Amid Clinical Trial Optimism and Advancing Dose Cohorts
Mar 13
4:41pm ET
Spruce Biosciences down 74% at $1.35 after resumption of trade
Mar 13
4:40pm ET
Spruce Biosciences Inc trading resumes
Mar 13
4:20pm ET
Spruce Biosciences to resume trading at 4:40 pm ET
Mar 13
4:18pm ET
Spruce Biosciences says ‘eager’ to report CAHmelia-204 topline results in Q3
Mar 13
4:16pm ET
Spruce Biosciences reports FY23 EPS ($1.24), consensus ($1.40)
Mar 13
4:10pm ET
Spruce Biosciences cuts workforce 21%, terminates CAHmelia-203 study
Mar 13
4:09pm ET
Spruce Biosciences says CAHmelia-203 study did not meet efficacy endpoint
Mar 13
4:06pm ET
Spruce Biosciences says Phase CAH study missed efficacy endpoint
Mar 13
4:03pm ET
Spruce Biosciences reports results from CAHmelia-203 study of tildacerfont
Mar 13
4:00pm ET
Spruce Biosciences Inc trading halted, news pending
Mar 07
8:51pm ET
Analysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)
Feb 27
8:30am ET
Three new option listings on February 27th
Feb 26
9:11am ET
Spruce Biosciences price target raised to $9 from $8 at RBC Capital
Feb 26
7:35am ET
Spruce Biosciences (SPRB) Gets a Buy from RBC Capital
Feb 21
7:08am ET
Guggenheim optimistic ahead of readouts, starts Spruce Biosciences at Buy
Feb 21
6:33am ET
Spruce Biosciences initiated with a Buy at Guggenheim
Feb 07
8:34am ET
Buy Rating on Spruce Biosciences: Anticipating Success with Tildacerfont amid a $2 Billion Market Opportunity
Jan 23
6:20am ET
Analysts Offer Insights on Healthcare Companies: Spruce Biosciences (SPRB) and Scilex Holding Company (SCLX)
Jan 23
12:30am ET
Analysts Offer Insights on Healthcare Companies: Spruce Biosciences (SPRB) and Inhibrx (INBX)
Jan 22
8:09am ET
Spruce Biosciences: enrollment in CAHmelia-204 study for CAH complete
Jan 09
1:21am ET
Analysts Are Bullish on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), Spruce Biosciences (SPRB)
Jan 05
6:27am ET
Buy Rating Affirmed for Spruce Biosciences Amid Positive Clinical Trials and Market Potential for Tildacerfont
Jan 04
12:10pm ET
Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Spruce Biosciences (SPRB)
Jan 04
8:11am ET
Spruce Biosciences: Cash equivalents as of December 31 $96M
Jan 04
8:09am ET
Spruce to report results of CAHmelia-203 and CAHptain-205 in March 2024
No recent news articles are available for SPRB
Mar 21
1:23pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
Mar 14
4:18pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
Mar 14
12:15pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRB
Mar 13
4:13pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. Incorporated and Encourages Investors with Losses to Contact the Firm
SPRB Financials
Key terms
Ad Feedback
SPRB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SPRB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range